Biogen, with $5.6B Apellis buy, builds out immunology offerings

BioPharma Dive

Chief Financial Officer Robin Kramer explained how the deal not only provides two marketed products, but a team with nephrology expertise that will be valuable as Biogen prepares to launch felzartamab

M&A / DealsImmunology & InflammationRead full story